Murthy, Sreenivasa
Aneja, Pankaj
Asirvatham, Arthur Joseph
Husemoen, Lise Lotte N.
Rhee, Nicolai A.
Kesavadev, Jothydev
Clinical trials referenced in this document:
Documents that mention this clinical trial
Understanding Patients’ Willingness to Pay for Biphasic Insulin Aspart 30/70 in a Pen Device for Type 2 Diabetes Treatment in an Out-of-Pocket Payment Market
https://doi.org/10.1007/s41669-020-00246-3
Funding for this research was provided by:
Novo Nordisk
Article History
Accepted: 10 December 2020
First Online: 6 January 2021
Declarations
:
: This study and article processing charges were funded by Novo Nordisk.
: NAR and LLNH are employees of the sponsor (at Novo Nordisk Health Care AG) and own shares in the company. JK is in the Speaker’s bureau for Novo Nordisk. SM, PA, and AJA have no conflicts of interest that are directly relevant to the content of this article.
: The study was conducted in accordance with Good Pharmacoepidemiology Practice (GPP), ethics review board approval, and the Declaration of Helsinki.
: Written informed consent was obtained from all individual participants included in the study before any study-related activities took place.
: Not applicable.
: The datasets generated and/or analyzed during the current study are available from the corresponding author on reasonable request.
: Not applicable.
: No authors have a related or duplicate manuscript under consideration or accepted for publication elsewhere.
: Study conception and design were contributed to by Lise Lotte Nystrup Husemoen, and Nicolai A. Rhee. Data collection was carried out by Sreenivasa Murthy, Pankaj Aneja, Arthur Asirvatham, and Jothydev Kesavadev. All authors critically reviewed the manuscript during the drafting stages and share in the final responsibility for the content of the manuscript, as well as the decision to submit it for publication.